GRAIL

Our #ASCO26 program highlights new data across #MCED testing, including detailed results from the NHS-Galleri trial, results from the PATHFINDER 2 study, and implementation insights in a private practice setting. See more: bit.ly/4nZhkF6 #EarlyCancerDetection

Want to stay up to date on all things GRAIL? Sign up for our newsletter to receive updates on the work we’re doing to shape the future of early cancer detection: bit.ly/44j6Jt6 #EarlyCancerDetection #CancerScreening #MCED

@maggie_hott @sweatystartup We are sorry to hear about this and take these reports seriously. Please contact us so we can learn more at galleri.com/support or call 833-694-2553.

@sweatystartup @GrailBio missed my pancreatic cancer diagnosis, but a preventive MRI caught it. I did both at the same time. Imo, the more tests the better as nothing is perfect.

Everybody with a net worth over $5 million should do a Grail Liquid Biopsy every year. My wife, me and my parents all do it annually. $1k to do it. Every 3 years for $1-5 million net worth. Can give you super early detection on 50 types of cancers.

Today GRAIL reported first quarter 2026 financial results. Read the press release: bit.ly/4nbY0E8

We will announce first quarter 2026 financial results on May 5. Register for the webcast: bit.ly/4mMtf8w Read more: bit.ly/3OTy9nG

At #ASCO26, we’re presenting primary results from the NHS-Galleri trial, the first randomized controlled study of an #MCED test, plus the full PATHFINDER 2 dataset. Together, this data strengthens evidence on MCED performance, safety, and clinical utility. 📊: bit.ly/42jLIjh

Research has shown that many patients with cancer are diagnosed through an emergency route, and these patients are more likely to have poor survival, even beyond the fact that they are also more likely to be diagnosed at a late stage. Patients diagnosed through more managed routes, such as cancer screening, are more likely to have early-stage disease and higher survival. At #AACR26, join us for a poster presentation exploring cancers first identified in the emergency department and what this route to diagnosis may reveal about patterns in cancer care. #CancerResearch #EarlyCancerDetection

We’re bringing new insights to #AACR26 across early cancer detection, screening behavior, and liquid biopsy research. First, explore GRAIL data on emergency presentation during cancer diagnosis and survival, as well as late-breaking research examining standard screening adherence following a negative multi-cancer early detection (MCED) test. Then, join us for an oral presentation in partnership with AstraZeneca exploring the potential role of ctDNA clearance in treatment monitoring for extensive-stage small cell lung cancer. #CancerScreening #CancerResearch #EarlyCancerDetection

Today we announced a collaboration with EPIC to integrate the Galleri multi-cancer early detection (#MCED) test into EPIC’s electronic health record (EHR) platform, supporting broader adoption across the US #HealthSystems. Read the press release: bit.ly/4t7ZzFd

Most cancer deaths are caused by cancers that don’t have a screening test. Multi-cancer early detection (#MCED) tests can detect signals for several cancers, catching them earlier, when it counts. Learn more: bit.ly/4ag0Sda #EarlyCancerDetection

Seven in 10 cancer deaths in the US are from cancers with no screening recommendations, including pancreatic, liver, ovarian, and more. Learn how multi-cancer early detection (#MCED) testing can help catch cancer earlier: bit.ly/3ZuUutm #EarlyCancerDetection

We recently celebrated 10 years of GRAIL across our sites and with our remote employees, recognizing all the people behind the incredible progress we have made in that time. Thank you to everyone who participated and helped bring this day to life. As we look to the next decade, we carry forward what started GRAIL in the first place: the curiosity to follow an unexpected signal, and the determination to turn possibility into progress – together. #GRAIL #EarlyCancerDetection

Five-year CCGA3 outcomes in @JCOPO_ASCO show that cancers with a cancer signal detected result using a blood-based multi-cancer early detection (#MCED) test had survival consistent with matched SEER populations, including early-stage disease. The MCED test was likely to find clinically significant cancers without contributing to overdiagnosis. Read the abstract: bit.ly/4s5ft2z The Galleri test does not detect a signal for all cancers, and false positive and false negative results can occur. Diagnostic testing is needed to confirm cancer.

Today we announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026. GRAIL’s Board of Directors has appointed the Company’s President, Josh Ofman, MD, MSHS, to serve as GRAIL’s Chief Executive Officer upon Ragusa’s retirement. Josh has also been appointed to serve on GRAIL’s Board of Directors, effective immediately. Josh’s appointment is the culmination of a long-term comprehensive succession planning process to ensure leadership continuity and strategic execution. Learn more: bit.ly/4blOdWC

As we celebrate GRAIL’s 10th anniversary this week, we reflect on the experiences of patients like Walt who inspire us to continue driving our critical work in early cancer detection. Walt had no reason to be worried about cancer - he had no symptoms and felt completely healthy. But results from a multi-cancer early detection test led to a diagnosis of a rare and aggressive cancer. His doctors noted that his kind of cancer is not normally diagnosed until stage three or four, but he was fortunate to have been diagnosed at stage one. At GRAIL we are focused on a future where more cancers are found earlier, when they may be more treatable, and more patients have the chance for better outcomes. That vision — and the patients at the heart of it — is what inspires us to keep moving forward.

#KidneyCancer can be difficult to detect. Early-stage tumors often cause no symptoms, small masses likely won’t be seen or felt during a routine exam, and there are no recommended screening tests for people at average risk. This #KidneyCancerAwareness Month, join us in highlighting the importance of early detection.

Today GRAIL reported fourth quarter and full year 2025 financial results. Read the press release: bit.ly/3OCVn0N

The NHS-Galleri trial enrolled more than 140,000 participants across England and evaluated the impact of multi-cancer screening with the Galleri test over a three-year period. View the topline results: bit.ly/3MTqWTB

We will announce fourth quarter and full year 2025 financial results on February 19. Register for the webcast: bit.ly/4rZLqcp Read more: bit.ly/3MHOevD

Following the President’s signature, the Nancy Gardner Sewell Medicare MCED Screening Coverage Act is now law, establishing a Medicare benefit category for MCED tests and a path to meaningful coverage once MCED tests are FDA approved. Learn more: bit.ly/45OQPdv